{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007821","form_type":"8-K","ticker":"INTI","cik":"0001042418","company_name":"Inhibitor Therapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.448058+00:00","generated_at":"2026-05-16T00:37:45.655290+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants","bullets":["Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.","Investor receives warrants to purchase up to 7,000,000 shares at $0.35/share, exercisable for 3 years.","Proceeds from the private placement will be used for working capital and general corporate purposes.","Shares and warrant shares are subject to a 9-month lock-up agreement that restricts resale.","Closing has not yet occurred; expected within a reasonable time after the filing date."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007821","json":"https://secwatch.observer/filing/0001493152-26-007821.json","markdown":"https://secwatch.observer/filing/0001493152-26-007821.md","text":"https://secwatch.observer/filing/0001493152-26-007821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/0001493152-26-007821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:37:45.655290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5a6acd9d4c1dde15b55a70a4bc9dfb90516b0f0","claim":"Inhibitor Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”), for certain financing (the “Financing”), pursuant to which the Company has agreed to sell to the Investor 12,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/0001493152-26-007821-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$3,000,000"},{"label":"Effective","value":"2026-02-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}